Le Lézard
Classified in: Health
Subjects: NPT, PER

Delta Dental Plans Association Names Dr. Joseph Dill as VP of Dental Science


OAK BROOK, Ill., March 22, 2018 /PRNewswire-USNewswire/ -- Delta Dental Plans Association (DDPA) has hired Joseph M. Dill, DDS, MBA to serve as its vice president, dental science & network strategy. In his role, Dr. Dill will oversee dental policy, network strategy and provide thought leadership for the Delta Dental brand. DDPA is the national association of the independent Delta Dental companies which make up the nation's leading dental insurance provider, with enrollment of over 75 million Americans.

Delta Dental Logo (PRNewsFoto/Delta Dental Plans Association)

Dr. Dill brings more than 30 years of experience in the dental field, including eight years in private dental practice and 16 years in the dental insurance industry. He most recently served as vice president of professional services and dental director for Delta Dental of Virginia (DDVA). In that role, he led DDVA's clinical professional services, dental policy, utilization management, fraud and abuse and quality care areas. Prior to joining DDVA, Dr. Dill spent eight years with Delta Dental of California where he served as their dental director ? western states region. 

"Joseph is a dental science thought leader with strong business and management skills," said Steven Olson, DDPA president and CEO. "With this combination of skills and expertise, he will be an asset to the DDPA team and lead the Systems dental policy and network strategy as we continue to fulfill our mission of expanding access to oral health care."

Dr. Dill also spent two years working for the U.S. Public Health Service as a commissioned officer where he provided dental care to residents of the Fort Peck Indian Reservation in Northern Montana. After eight years managing a private practice, he returned to business school and was co-founder and COO for Propel Biomedical Consulting where he helped biomedical firms achieve financial success through comprehensive commercialization strategies. Additionally, he founded a start-up medical device company, Otoimage, Inc. to develop a reliable means of diagnosing otitis media in infants and children.  He also worked at Premera Blue Cross in Washington and Alaska as director of dental products.     

Dr. Dill earned his dental degree and bachelor's degree from the University of the Pacific. He also holds a masters of business administration from the University of California at Irvine. 

Follow us on Twitter @DeltaDental and Facebook: Delta Dental Plans Association

About Delta Dental Plans Association
Delta Dental Plans Association, based in Oak Brook, Ill., is the not-for-profit national association of the 39 independent Delta Dental companies.  Through its companies, Delta Dental is the nation's leading dental insurance provider, covering more than 75 million Americans, and offering the country's largest dental network with roughly 152,000 participating dentists. Delta Dental companies invested more than 69 million dollars in 2016 to help improve oral healthcare in local communities across the country. For more information, visit our website at deltadental.com.

SOURCE Delta Dental Plans Association


These press releases may also interest you

at 16:10
Acadia Pharmaceuticals Inc. today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 8,...

at 16:10
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May...

at 16:05
BeiGene, Ltd. , a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024....

at 16:05
Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin...

at 16:05
Arrowhead Pharmaceuticals, Inc. today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and...

at 16:05
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of...



News published on and distributed by: